Peripheral brain-derived neurotrophic factor (BDNF) as a biomarker in bipolar disorder: A meta-analysis of 52 studies

BMC Medicine

Volumn 13, Issue 1, 2015, Pages

  Fernandes, Brisa S ^a,b   Molendijk, Marc L ^c,d   Köhler, Cristiano A ^e   Soares, Jair C ^f   Leite, Cláudio Manuel G S ^e   Machado Vieira, Rodrigo ^g,h   Ribeiro, Thamara L ^e   Silva, Jéssica C ^e   Sales, Paulo M G ^e   Quevedo, João ^f,i,j,k   Oertel Knöchel, Viola ^l   Vieta, Eduard ^m   González Pinto, Ana ⁿ   Berk, Michael ^a,o,p   Carvalho, André F ^e  

^a DEAKIN UNIVERSITY   (Australia)

^b FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^c LEIDEN UNIVERSITY   (Netherlands)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^e FEDERAL UNIVERSITY OF CEARÁ   (Brazil)

^f University of Texas Health Sciences   (United States)

^g UNIVERSITY OF SÃO PAULO   (Brazil)

^h NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

ⁱ UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^j UNIVERSITY OF TEXAS   (United States)

^k UNIVERSITY OF SOUTHERN SANTA CATARINA   (Brazil)

^l GOETHE UNIVERSITY   (Germany)

^m UNIVERSITY OF BARCELONA   (Spain)

ⁿ UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^o THE NATIONAL CENTRE OF EXCELLENCE IN YOUTH MENTAL HEALTH   (Australia)

^p UNIVERSITY OF MELBOURNE   (Australia)

more..

Author keywords

Biomarker; Bipolar disorder; Brain derived neurotrophic factor; Meta analysis

Indexed keywords

BIOLOGICAL MARKER; BRAIN DERIVED NEUROTROPHIC FACTOR; BRAIN-DERIVED NEUROTROPHIC FACTOR, HUMAN;

AGE DISTRIBUTION; ARTICLE; BIPOLAR DISORDER; BLOOD; COMPARATIVE STUDY; CROSS-SECTIONAL STUDY; DEMOGRAPHY; DEPRESSION; DISEASE ACTIVITY; DISEASE DURATION; DISEASE SEVERITY; EFFECT SIZE; HUMAN; LONGITUDINAL STUDY; MANIA; META ANALYSIS; META REGRESSION ANALYSIS; PLASMA; PROTEIN BLOOD LEVEL; PUBLISHING; REGRESSION ANALYSIS; SENSITIVITY ANALYSIS; SERUM; SYMPTOMATOLOGY; SYSTEMATIC REVIEW; TREATMENT OUTCOME; FEMALE; GENETICS; MALE; METABOLISM; MIDDLE AGED;

BIOMARKERS; BIPOLAR DISORDER; BRAIN-DERIVED NEUROTROPHIC FACTOR; DEPRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED;

EID: 84959135514     PISSN: None     EISSN: 17417015     Source Type: Journal    
DOI: 10.1186/s12916-015-0529-7     Document Type: Article

References (108)

1. Barde YA, Edgar D, Thoenen H. Purification of a new neurotrophic factor from mammalian brain. EMBO J. 1982;1(5):549-53.
2. Levi-Montalcini R, Hamburger V. Selective growth stimulating effects of mouse sarcoma on the sensory and sympathetic nervous system of the chick embryo. J Exp Zool. 1951;116(2):321-61.
3. Duman RS, Heninger GR, Nestler EJ. A molecular and cellular theory of depression. Arch Gen Psychiatry. 1997;54(7):597-606.
4. Karege F, Perret G, Bondolfi G, Schwald M, Bertschy G, Aubry JM. Decreased serum brain-derived neurotrophic factor levels in major depressed patients. Psychiatry Res. 2002;109(2):143-8.
5. Kuhn T. The structure of scientific revolutions. 4th ed. Chicago: The University of Chicago Press; 1962.
6. Toyooka K, Asama K, Watanabe Y, Muratake T, Takahashi M, Someya T, et al. Decreased levels of brain-derived neurotrophic factor in serum of chronic schizophrenic patients. Psychiatry Res. 2002;110(3):249-57.
7. Laske C, Stransky E, Eschweiler GW, Wittorf A, Richartz-Salzburger E, Bartels M, et al. Brain-derived neurotrophic factor (BDNF) in serum of patients with mania, major depression and healthy controls. Neurol Psychiatry Brain Res. 2005;12(1):25-8.
8. Palomino A, Vallejo-Illarramendi A, Gonzalez-Pinto A, Aldama A, Gonzalez-Gomez C, Mosquera F, et al. Decreased levels of plasma BDNF in first-episode schizophrenia and bipolar disorder patients. Schizophr Res. 2006;86(1-3):321-2.
9. Fernandes BS, Gama CS, Kauer-Sant'Anna M, Lobato MI, Belmonte-de-Abreu P, Kapczinski F. Serum brain-derived neurotrophic factor in bipolar and unipolar depression: a potential adjunctive tool for differential diagnosis. J Psychiatr Res. 2009;43(15):1200-4.
10. Frey BN, Andreazza AC, Houenou J, Jamain S, Goldstein BI, Frye MA, et al. Biomarkers in bipolar disorder: a positional paper from the International Society for Bipolar Disorders Biomarkers Task Force. Aust N Z J Psychiatry. 2013;47(4):321-32.
11. Kapczinski F, Fernandes BS, Kauer-Sant'Anna M, Gama CS, Yatham LN, Berk M. The concept of staging in bipolar disorder: the role of BDNF and TNF-alpha as biomarkers. Acta Neuropsychiatrica. 2009;21(6):272-4.
12. Pan W, Banks WA, Fasold MB, Bluth J, Kastin AJ. Transport of brain-derived neurotrophic factor across the blood-brain barrier. Neuropharmacology. 1998;37(12):1553-61.
13. Karege F, Schwald M, Cisse M. Postnatal developmental profile of brain-derived neurotrophic factor in rat brain and platelets. Neurosci Lett. 2002;328(3):261-4.
14. Fernandes BS, Gama CS, Maria Cereser K, Yatham LN, Fries GR, Colpo G, et al. Brain-derived neurotrophic factor as a state-marker of mood episodes in bipolar disorders: a systematic review and meta-regression analysis. J Psychiatr Res. 2011;45(8):995-1004.
15. Lin PY. State-dependent decrease in levels of brain-derived neurotrophic factor in bipolar disorder: a meta-analytic study. Neurosci Lett. 2009;466(3):139-43.
16. Fernandes BS, Berk M, Turck CW, Steiner J, Goncalves CA. Decreased peripheral brain-derived neurotrophic factor levels are a biomarker of disease activity in major psychiatric disorders: a comparative meta-analysis. Mol Psychiatry. 2014;19(7):749-51.
17. Fernandes BS, Gomes FA, Fries G, Stertz L, Cereser KM, Pessoa C, et al. Brain-derived neurotrophic factor as a possible biomarker of bipolar disorder activity. Bipolar Disord. 2010;12:19.
18. Fernandes BS, Steiner J, Bernstein HG, Dodd S, Pasco JA, Dean OM, et al. C-reactive protein is increased in schizophrenia but is not altered by antipsychotics: meta-analysis and implications. Mol Psychiatry. 2015 Jul 14. doi: 10.1038/mp.2015.87. [Epub ahead of print].
19. Rosa AR, Gonzalez-Ortega I, Gonzalez-Pinto A, Echeburua E, Comes M, Martinez-Aran A, et al. One-year psychosocial functioning in patients in the early vs. late stage of bipolar disorder. Acta Psychiatr Scand. 2012;125(4):335-41.
20. Davis J, Maes M, Andreazza A, McGrath JJ, Tye SJ, Berk M. Towards a classification of biomarkers of neuropsychiatric disease: from encompass to compass. Mol Psychiatry. 2015;20(2):152-3.
21. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. The Cochrane Collaboration, 2011. The Cochrane Collaboration. http://www.cochrane-handbook.org.
22. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000;283(15):2008-12.
23. Lau J, Ioannidis JP, Schmid CH. Quantitative synthesis in systematic reviews. Ann Intern Med. 1997;127(9):820-6.
24. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539-58.
25. Munkholm K, Vinberg M, Kessing LV. Peripheral blood brain-derived neurotrophic factor in bipolar disorder: a comprehensive systematic review and meta-analysis. Mol Psychiatry. 2015. Ahead of print. doi: 10.1038/mp.2015.54.
26. Polyakova M, Stuke K, Schuemberg K, Mueller K, Schoenknecht P, Schroeter ML. BDNF as a biomarker for successful treatment of mood disorders: a systematic & quantitative meta-analysis. J Affect Disord. 2015;174:432-40.
27. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol. 2009;62(10):1006-12.
28. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23(1):56.
29. Sistrom CL, Mergo PJ. A simple method for obtaining original data from published graphs and plots. AJR Am J Roentgenol. 2000;174(5):1241-4.
30. Dwan K, Gamble C, Williamson PR, Kirkham JJ. Systematic review of the empirical evidence of study publication bias and outcome reporting bias - an updated review. PLoS One. 2013;8(7), e66844.
31. Young SS, Bang H. The file-drawer problem, revisited. Sci. 2004;306(5699):1133-4. Author reply 1133-1134.
32. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629-34.
33. Belbasis L, Bellou V, Evangelou E, Ioannidis JP, Tzoulaki I. Environmental risk factors and multiple sclerosis: an umbrella review of systematic reviews and meta-analyses. Lancet Neurol. 2015;14(3):263-73.
34. 2 index? Psychol Methods. 2006;11(2):193.
35. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557-60.
36. Higgins JP, Thompson SG, Spiegelhalter DJ. A re-evaluation of random-effects meta-analysis. J R Stat Society Ser A. 2009;172(1):137-59.
37. Higgins JP. Commentary: Heterogeneity in meta-analysis should be expected and appropriately quantified. Int J Epidemiol. 2008;37(5):1158-60.
38. Higgins J, Green, S. Cochrane Handbook for systematic reviews of interventions version 5.0. 2 [updated September 2009]. The Cochrane Collaboration, 2009. www.cochrane-handbook.org. Accessed 18 August 2014.
39. Faul F, Erdfelder E, Buchner A, Lang AG. Statistical power analyses using G*Power 3.1: tests for correlation and regression analyses. Behav Res Methods. 2009;41(4):1149-60.
40. Ioannidis JP, Trikalinos TA. An exploratory test for an excess of significant findings. Clin Trials. 2007;4(3):245-53.
41. Munkholm K, Pedersen BK, Kessing LV, Vinberg M. Elevated levels of plasma brain derived neurotrophic factor in rapid cycling bipolar disorder patients. Psychoneuroendocrinology. 2014;47:199-211.
42. Andreazza AC, Rajji TK, Gildengers A, Soares AT, Lafer B, Young LT, et al. Decrease brain-derived neurotrophic factor (BDNF) in older patients with bipolar disorder. Biol Psychiatry. 2014;1:41S.
43. Barbosa IG, Huguet RB, Mendonca VA, Neves FS, Reis HJ, Bauer ME, et al. Increased plasma levels of brain-derived neurotrophic factor in patients with long-term bipolar disorder. Neurosci Lett. 2010;475(2):95-8.
44. Barbosa IG, Rocha NP, de Miranda AS, Huguet RB, Bauer ME, Reis HJ, et al. Increased BDNF levels in long-term bipolar disorder patients. Rev Bras Psiquiatr. 2013;35(1):67-9.
45. Barbosa IG, Rocha NP, Huguet RB, Ferreira RA, Salgado JV, Carvalho LA, et al. Executive dysfunction in euthymic bipolar disorder patients and its association with plasma biomarkers. J Affect Disord. 2012;137(1-3):151-5.
46. Ceylan D, Ozerdem A, Gurz Yalcin SN, Hidirotlu C, Aslan YC, Batci B, et al. Can serum BDNF levels be identified as a candidate endophenotype in bipolar disorder? Bipolar Disord. 2012;14:66.
47. Chen SL, Lee SY, Chang YH, Chen SH, Chu CH, Wang TY, et al. The BDNF Val66Met polymorphism and plasma brain-derived neurotrophic factor levels in Han Chinese patients with bipolar disorder and schizophrenia. Prog Neuro-Psychopharmacol Biol Psychiatry. 2014;51:99-104.
48. Chou YH, Wang SJ, Lirng JF, Lin CL, Yang KC, Chen CK, et al. Impaired cognition in bipolar I disorder: the roles of the serotonin transporter and brain-derived neurotrophic factor. J Affect Disord. 2012;143(1-3):131-7.
49. Cunha AB, Frey BN, Andreazza AC, Goi JD, Rosa AR, Goncalves CA, et al. Serum brain-derived neurotrophic factor is decreased in bipolar disorder during depressive and manic episodes. Neurosci Lett. 2006;398(3):215-9.
50. de Oliveira GS, Cereser KM, Fernandes BS, Kauer-Sant'Anna M, Fries GR, Stertz L, et al. Decreased brain-derived neurotrophic factor in medicated and drug-free bipolar patients. J Psychiatr Res. 2009;43(14):1171-4.
51. de Sousa RT, van de Bilt MT, Diniz BS, Ladeira RB, Portela LV, Souza DO, et al. Lithium increases plasma brain-derived neurotrophic factor in acute bipolar mania: a preliminary 4-week study. Neurosci Lett. 2011;494(1):54-6.
52. Dell'Osso L, Bianchi C, Del Debbio A, Roncaglia I, Veltri A, Carlini M, et al. Plasma brain-derived neurotrophic factor in bipolar and unipolar depression. Ital J Psychopathol. 2010;16(2):138-43.
53. Dias VV, Brissos S, Frey BN, Andreazza AC, Cardoso C, Kapczinski F. Cognitive function and serum levels of brain-derived neurotrophic factor in patients with bipolar disorder. Bipolar Disord. 2009;11(6):663-71.
54. F PBW-ABPSLCMVEFMKMK. Evaluation of peripheral biomarkers in bipolar and unipolar depression. Eur Neuropsychopharmacol. 2013;23(2):361-2.
55. Goka E, Goka S, Aydemir C, Aksaray S, Yalcin ES, Kisa C. [BDNF levels and change with treatment in patients with bipolar disorder manik episode.] Klin Psikofarmakoloji Bulteni. 2009;19 Suppl 1:S8-S13. In Turkish.
56. Grande I, Kapczinski F, Stertz L, Colpo GD, Kunz M, Cereser KM, et al. Peripheral brain-derived neurotrophic factor changes along treatment with extended release quetiapine during acute mood episodes: An open-label trial in drug-free patients with bipolar disorder. J Psychiatr Res. 2012;46(11):1511-4.
57. Grande I, Magalhaes PV, Chendo I, Stertz L, Fries GR, Cereser KM, et al. Val66Met polymorphism and serum brain-derived neurotrophic factor in bipolar disorder: an open-label trial. Acta Psychiatr Scand. 2014;129(5):393-400.
58. Hsieh WC, Jou YT, Lin JL, Wang SJ, Chou YH. The effect of cortisol and BDNF on serotonin transporter in bipolar I disorder. Bipolar Disord. 2014;16:89.
59. Huang TL, Hung YY, Lee CT, Chen RF. Serum protein levels of brain-derived neurotrophic factor and tropomyosin-related kinase B in bipolar disorder: effects of mood stabilizers. Neuropsychobiology. 2012;65(2):65-9.
60. Kapczinski F, Dal-Pizzol F, Teixeira AL, Magalhaes PV, Kauer-Sant'Anna M, Klamt F, et al. Peripheral biomarkers and illness activity in bipolar disorder. J Psychiatr Res. 2011;45(2):156-61.
61. Karamustafalioglu N, Genc A, Kalelioglu T, Tasdemir A, Umut G, Incir S, et al. Plasma BDNFs level initially and post treatment in acute mania: comparison between ECT and atypical antipsychotic treatment and healthy controls. J Psychopharmacol. 2015;29(8):898-902.
62. Kauer-Sant'Anna M, Kapczinski F, Andreazza AC, Bond DJ, Lam RW, Young L, et al. Brain-derived neurotrophic factor and inflammatory markers in patients with early- vs. late-stage bipolar disorder. Int J Neuropsychopharmacol. 2009;12(4):447-58.
63. Kenna HA, Reynolds-May M, Stepanenko A, Ketter TA, Hallmayer J, Rasgon NL. Blood levels of brain derived neurotrophic factor in women with bipolar disorder and healthy control women. J Affect Disord. 2014;156:214-8.
64. Kim Y-K, Na K-S, Hwang J-A, Yoon H-K, Lee H-J, Hahn S-W, et al. High insulin-like growth factor-1 in patients with bipolar I disorder: a trait marker? J Affect Disord. 2013;151(2):738-43.
65. Kurita M, Nishino S, Numata Y, Okubo Y, Sato T. The noradrenaline metabolite MHPG is a candidate biomarker from the manic to the remission state in bipolar disorder I: a clinical naturalistic study. PLoS One. 2014;9(6), e100634.
66. Langan C, Doyle K, Kelly J, Emsell L, Skinner R, McDonald C. Serum BDNF levels in euthymic bipolar disorder: Preliminary results from the Galway bipolar study. Bipolar Disord. 2009;11(S1):56.
67. Lee SY, Chen SL, Chang YH, Chen PS, Huang SY, Tzeng NS, et al. Correlation of plasma brain-derived neurotrophic factor and metabolic profiles in drug-naive patients with bipolar II disorder after a twelve-week pharmacological intervention. Acta Psychiatrica Scandinavica. 2015;131(2):120-8.
68. Li Z, Zhang C, Fan J, Yuan C, Huang J, Chen J, et al. Brain-derived neurotrophic factor levels and bipolar disorder in patients in their first depressive episode: 3-year prospective longitudinal study. Br J Psychiatry. 2014;205(1):29-35.
69. Lotrich FE, Butters MA, Aizenstein H, Marron MM. Reynolds 3rd CF, Gildengers AG. The relationship between interleukin-1 receptor antagonist and cognitive function in older adults with bipolar disorder. Int J Geriatr Psychiatry. 2014;29(6):635-44.
70. Machado-Vieira R, Dietrich MO, Leke R, Cereser VH, Zanatto V, Kapczinski F, et al. Decreased plasma brain derived neurotrophic factor levels in unmedicated bipolar patients during manic episode. Biol Psychiatry. 2007;61(2):142-4.
71. Mackin P, Gallagher P, Watson S, Young A, Ferrier IN. Changes in brain-derived neurotrophic factor following treatment with mifepristone in bipolar disorder and schizophrenia. Aust N Z J Psychiatry. 2007;41(4):321-6.
72. Magalhaes PV, Jansen K, Pinheiro RT, Fries GR, Teixeira AL, Da Silva RA, et al. A nested population-based case-control study on peripheral inflammation markers and brain-derived neurotrophic factor in early-stage mood disorders. Bipolar Disord. 2012;14:48.
73. Monteleone P, Serritella C, Martiadis V, Maj M. Decreased levels of serum brain-derived neurotrophic factor in both depressed and euthymic patients with unipolar depression and in euthymic patients with bipolar I and II disorders. Bipolar Disord. 2008;10(1):95-100.
74. Panizzutti BS, Gubert C, Schuh AL, Ferrari P, Bristot G, Fries GR, et al. Increased serum levels of CCL11/eotaxin in late stage bipolar patients. Biol Psychiatry. 2014;1:183S.
75. Piccinni A, Veltri A, Costanzo D, Vanelli F, Franceschini C, Moroni I, et al. Decreased plasma levels of brain-derived neurotrophic factor (BDNF) during mixed episodes of bipolar disorder. J Affect Disord. 2014;171c:167-70.
76. Rabie MA, Mohsen M, Ibrahim M, El-Sawy Mahmoud R. Serum level of brain derived neurotrophic factor (BDNF) among patients with bipolar disorder. J Affect Disord. 2014;162:67-72.
77. Rosa AR, Singh N, Whitaker E, de Brito M, Lewis AM, Vieta E, et al. Altered plasma glutathione levels in bipolar disorder indicates higher oxidative stress; a possible risk factor for illness onset despite normal brain-derived neurotrophic factor (BDNF) levels. Psychol Med. 2014;44:2409-18.
78. Rybakowski JK, Permoda-Osip A, Skibinska M, Adamski R, Bartkowska-Sniatkowska A. Single ketamine infusion in bipolar depression resistant to antidepressants: are neurotrophins involved? Hum Psychopharmacol. 2013;28(1):87-90.
79. Rybakowski JK, Suwalska A. Excellent lithium responders have normal cognitive functions and plasma BDNF levels. Int J Neuropsychopharmacol. 2010;13(5):617-22.
80. Sodersten K, Palsson E, Ishima T, Funa K, Landen M, Hashimoto K, et al. Abnormality in serum levels of mature brain-derived neurotrophic factor (BDNF) and its precursor proBDNF in mood-stabilized patients with bipolar disorder: a study of two independent cohorts. J Affect Disord. 2014;160:1-9.
81. Su SC, Sun MT, Wen MJ, Lin CJ, Chen YC, Hung YJ. Brain-derived neurotrophic factor, adiponectin, and proinflammatory markers in various subtypes of depression in young men. Int J Psychiatry Med. 2011;42(3):211-26.
82. Suwalska A, Sobieska M, Rybakowski J. Serum brain-derived neurotrophic factor in euthymic bipolar patients on prophylactic lithium therapy. Neuropsychobiology. 2010;62(4):229-34.
83. Tramontina J, Frey B, Andreazza A, Zandona M, Santin A, Kapczinski F. Val66met polymorphism and serum brain-derived neurotrophic factor levels in bipolar disorder. Mol Psychiatry. 2007;12(3):230-1.
84. Tramontina JF, Andreazza AC, Kauer-Sant'anna M, Stertz L, Goi J, Chiarani F, et al. Brain-derived neurotrophic factor serum levels before and after treatment for acute mania. Neurosci Lett. 2009;452(2):111-3.
85. Tunca Z, Kivircik Akdede B, Ozerdem A, Alkin T, Polat S, Ceylan D, et al. Diverse glial cell line-derived neurotrophic factor (GDNF) support between mania and schizophrenia: a comparative study in four major psychiatric disorders. Eur Psychiatry. 2015;30(2):198-204.
86. Tunca Z, Ozerdem A, Ceylan D, Yalcin Y, Can G, Resmi H, et al. Alterations in BDNF (brain derived neurotrophic factor) and GDNF (glial cell line-derived neurotrophic factor) serum levels in bipolar disorder: the role of lithium. J Affect Disord. 2014;166:193-200.
87. Wang ZW, Li ZZ, Lin ZG, Wu ZG, Yuan CM, Hong W, et al. Changes of plasma brain-derived neurotrophic factor in patients with bipolar disorder type I. J Shanghai Jiaotong Univ. 2011;31(11):1532-5.
88. Ye C, Xu Y, Hu H. The serum concentration of brain-derived neurotrophic factor (BDNF) increased after four weeks treatment in acute mania patients. Int J Neuropsychopharmacol. 2010;13:133.
89. Yoshimura R, Ikenouchi-Sugita A, Hori H, Umene-Nakano W, Katsuki A, Hayashi K, et al. Adding a low dose atypical antipsychotic drug to an antidepressant induced a rapid increase of plasma brain-derived neurotrophic factor levels in patients with treatment-resistant depression. Prog Neuro-Psychopharmacol Biol Psychiatry. 2010;34(2):308-12.
90. Yoshimura R, Nakano Y, Hori H, Ikenouchi A, Ueda N, Nakamura J. Effect of risperidone on plasma catecholamine metabolites and brain-derived neurotrophic factor in patients with bipolar disorders. Hum Psychopharmacol. 2006;21(7):433-8.
91. Molendijk ML, Spinhoven P, Polak M, Bus BA, Penninx BW, Elzinga BM. Serum BDNF concentrations as peripheral manifestations of depression: evidence from a systematic review and meta-analyses on 179 associations (N = 9484). Mol Psychiatry. 2014;19(7):791-800.
92. Munkholm K, Peijs L, Vinberg M, Kessing LV. A composite peripheral blood gene expression measure as a potential diagnostic biomarker in bipolar disorder. Transl Psychiatry. 2015;5, e614.
93. Niculescu AB, Le-Niculescu H, Patel S, Bhat M, Kuczenski R, Faraone SV, et al. Convergent functional genomics of genome-wide association data for bipolar disorder: Comprehensive identification of candidate genes, pathways and mechanisms. Biol Psychiatry. 2009;1:170S.
94. Fernandes BS, Steiner J, Berk M, Molendijk ML, Gonzalez-Pinto A, Turck CW, et al. Peripheral brain-derived neurotrophic factor in schizophrenia and the role of antipsychotics: meta-analysis and implications. Mol Psychiatry. 2015;20(9):1108-19.
95. Carvalho AF, Kohler CA, McIntyre RS, Knochel C, Brunoni AR, Thase ME, et al. Peripheral vascular endothelial growth factor as a novel depression biomarker: a meta-analysis. Psychoneuroendocrinology. 2015;62:18-26.
96. Berk M, Kapczinski F, Andreazza AC, Dean OM, Giorlando F, Maes M, et al. Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neurosci Biobehav Rev. 2011;35(3):804-17.
97. Kapczinski F, Magalhaes PV, Balanza-Martinez V, Dias VV, Frangou S, Gama CS, et al. Staging systems in bipolar disorder: an International Society for Bipolar Disorders Task Force Report. Acta Psychiatr Scand. 2014;130(5):354-63.
98. Berk M, Berk L, Dodd S, Cotton S, Macneil C, Daglas R, et al. Stage managing bipolar disorder. Bipolar Disord. 2014;16(5):471-7.
99. Bus BA, Molendijk ML, Tendolkar I, Penninx BW, Prickaerts J, Elzinga BM, et al. Chronic depression is associated with a pronounced decrease in serum brain-derived neurotrophic factor over time. Mol Psychiatry. 2015;20(5):602-8.
100. Vieta E. Staging and psychosocial early intervention in bipolar disorder. Lancet Psychiatry. 2015;2(6):483-5.
101. Gonzalez-Castro TB, Nicolini H, Lanzagorta N, Lopez-Narvaez L, Genis A, Pool Garcia S, et al. The role of brain-derived neurotrophic factor (BDNF) Val66Met genetic polymorphism in bipolar disorder: a case-control study, comorbidities, and meta-analysis of 16,786 subjects. Bipolar Disord. 2015;17(1):27-38.
102. Harrisberger F, Smieskova R, Schmidt A, Lenz C, Walter A, Wittfeld K, et al. BDNF Val66Met polymorphism and hippocampal volume in neuropsychiatric disorders: a systematic review and meta-analysis. Neurosci Biobehav Rev. 2015;55:107-18.
103. Klein AB, Williamson R, Santini MA, Clemmensen C, Ettrup A, Rios M, et al. Blood BDNF concentrations reflect brain-tissue BDNF levels across species. Int J Neuropsychopharmacol. 2011;14(3):347-53.
104. Dawood T, Anderson J, Barton D, Lambert E, Esler M, Hotchkin E, et al. Reduced overflow of BDNF from the brain is linked with suicide risk in depressive illness. Mol Psychiatry. 2007;12(11):981-3.
105. Rizos EN, Michalopoulou PG, Siafakas N, Stefanis N, Douzenis A, Rontos I, et al. Association of serum brain-derived neurotrophic factor and duration of untreated psychosis in first-episode patients with schizophrenia. Neuropsychobiology. 2010;62(2):87-90.
106. Pillai A, Kale A, Joshi S, Naphade N, Raju MS, Nasrallah H, et al. Decreased BDNF levels in CSF of drug-naive first-episode psychotic subjects: correlation with plasma BDNF and psychopathology. Int J Neuropsychopharmacol. 2010;13(4):535-9.
107. Fujimura H, Altar CA, Chen R, Nakamura T, Nakahashi T, Kambayashi J, et al. Brain-derived neurotrophic factor is stored in human platelets and released by agonist stimulation. Thromb Haemost. 2002;87(4):728-34.
108. Baseri B, Choi JJ, Deffieux T, Samiotaki G, Tung YS, Olumolade O, et al. Activation of signaling pathways following localized delivery of systemically administered neurotrophic factors across the blood-brain barrier using focused ultrasound and microbubbles. Phys Med Biol. 2012;57(7):N65-81.